标签归档 广州蒲友网

　　CCTV News:According to Weibo released by @ Jiexiu, on August 26th, Jiexiu City successively issued the Notice of Jiexiu City on Implementing Static Management in the City, the Notice of Jiexiu City on Carrying out Preventive All-staff Nucleic Acid Detection in the City, and the Notice of Jiexiu City Public Security Bureau on Temporary Road Traffic Control.

　　According to the circular, Jiexiu City received an investigation letter from Jinzhong City, informing that the positive cases in Qingxu County and xiaodian district of Taiyuan City had an activity track in Jiexiu City. According to the current epidemic situation, in order to protect people’s life safety and health, and prevent the spread of the epidemic, the leading group for the prevention and control of pneumonia infected in novel coronavirus decided to implement static management in the city. Static management time: 13: 00 on August 26th & mdash; 24:00 on August 28th. During the period, the whole city remained silent, and it was necessary not to go out. In principle, it was necessary to stay at home. All personnel are subject to "three inspections in three days", and key personnel are subject to the original control measures.

　　According to the notice, all motor vehicles are prohibited from passing on the road during the static management period (except for epidemic prevention and control, special vehicles performing tasks), and red light control monitoring equipment is enabled at all intersections in the city, and violations of the notice will be dealt with according to law.

　　Notice of Jiexiu Municipality on Implementing Static Management in the City

　　On August 26th, 2022, at 02:00 and 3:24, our city received the investigation letter from Jinzhong City, informing that the positive cases in Qingxu County and xiaodian district of Taiyuan City had an activity track in our city. According to the current epidemic situation, in order to protect people’s life safety and health, and prevent the spread of the epidemic, the leading group for the prevention and control of pneumonia infected in novel coronavirus decided to implement static management in the city.　

　　1. Static management time: from 13: 00 on August 26th & mdash; Static management was implemented at 24:00 on August 28th. During the period, the whole city remained silent, and it was necessary not to go out. In principle, it was necessary to stay at home. All personnel are subject to "three inspections in three days", and key personnel are subject to the original control measures.

　　Two, the implementation of traffic control, railway stations, train stations, bus stations, high-speed intersections to limit the flow of people, the implementation of traffic control. The city’s guaranteed supply, production, stability and epidemic prevention vehicles pass through, and the guaranteed supply enterprises "point-to-point" pick up and drop off, and social vehicles that do not meet the requirements do not run or flow.

　　Three, in addition to the supermarket, pharmacy and medical institutions and other places, the rest of the business premises will be suspended offline business. Institutions, enterprises and institutions and various social organizations do not hold gathering activities.

　　Four, all kinds of kindergartens, off-campus training institutions to stop offline teaching, boarding schools have started, with closed conditions, the implementation of closed management, closed-loop operation. Old-age care institutions implement closed management and do not visit unless necessary. All project sites under construction in the area shall be managed in a closed way and operated in a closed loop.

　　Five, all kinds of clinics and pharmacies to suspend the "one refund and two resistance" sales. Any person with a history of living in a key epidemic-related area shall be reported to the relevant competent department immediately.

　　Six, the masses do not have to leave the city, to introduce tourists to live in hotels, guesthouses, inns, homestays in silence on the spot, in accordance with the provisions of the nucleic acid testing.

　　Seven, within the scope of regional control in-service party member to bright identity, on-the-spot active investment in epidemic prevention and control work, service community treatment and transshipment, nucleic acid sampling and publicity, living materials security, community service security, policy propaganda, emotional comfort, psychological counseling, order maintenance and other work.

　　Eight, the city to the community (village) as a unit, to co-ordinate the establishment of nucleic acid testing sampling points, in accordance with the designated time and place to carry out all the nucleic acid testing. Please actively cooperate with the general public, follow the arrangement of the street (township) and community (village) to go to the sampling point, and complete the sampling work according to the guidance of the staff. When testing, please bring your ID card and take the initiative to show the "sampling code". Please wear a mask all the time during the collection process, and keep a distance of more than 2 meters from others, without talking or gathering.

　　Nine, fever, cough and other symptoms report to the community (village) at the first time, in accordance with the relevant provisions of the epidemic prevention and control to the fever clinic, it is strictly prohibited to conceal, omit or delay the report.

　　Ten, severely punish violations of laws and regulations. At present, the city has sufficient reserves of living materials. Please do not panic, make rumors, believe in rumors or spread rumors. The public security organs will investigate the relevant responsibilities of those who refuse to cooperate, disturb the order, make rumors and create troubles, and conceal, falsely report or falsify information. 　

　　Jiexiu novel coronavirus infected pneumonia epidemic prevention and control work leading team office

　　August 26th, 2022 　 　 　

　　Notice of Jiexiu city on carrying out preventive nucleic acid testing for all employees in the city

　　In view of the current grim situation of epidemic prevention and control, in order to effectively protect people’s health and life safety, according to the research of the Municipal Leading Group for Epidemic Prevention and Control, it is decided to conduct static management of the whole city from August 26 to August 28, and carry out preventive full-time nucleic acid testing. The specific arrangements are as follows:

　　First, the static management time starts at 13:00 on August 26th, 2022. During the static management period, the people in the whole city will stay at home, so as to "stay inside, stay outside, and stay inside". In principle, they must stay at home.

　　Second, the sampling range and requirements

　　1. Take the village and community as the unit and the grid as the smallest unit, set up nucleic acid sampling points as a whole, and carry out all-staff nucleic acid testing at the designated time and place. In order to complete the nucleic acid detection as soon as possible, residents are requested to actively cooperate, follow the arrangement of the village and the community, go to the sampling point, bring their resident ID cards, and log in to WeChat "Jinzhong Nucleic Acid Detection Terminal" in advance to generate a sampling code (screen capture can be saved, or a paper version can be printed in advance).

　　2. Please wear a mask throughout the collection process, keep a distance of more than 2 meters from others, and return immediately without talking or gathering.

　　3. Those who have not been vaccinated with Covid-19 vaccine for more than 48 hours will not participate in the full-time nucleic acid test after reporting to the community (village) where they live.

　　Third, matters needing attention

　　1. During the whole staff nucleic acid test, temporary traffic control will be implemented in the whole city. Except for special vehicles such as police cars, fire engines, ambulances, garbage trucks and material support vehicles, other social vehicles are not allowed to drive on the road. Only three high-speed exits, train stations, railway stations and Sanxian Avenue are reserved in the referral channel, and the original mechanism and process are maintained to work normally, so that the referral personnel can collect nucleic acids on the spot. In principle, you can’t get in or out, and the rest of the staff are strictly in a static state at their current residence, and they don’t flow at home. 　　

　　2. Except for large factories, mines and enterprises related to people’s livelihood security and production safety, other enterprises suspend production; Restaurants, entertainment and other business stores are closed. Departments in charge of various industries should promptly notify enterprises and business premises in various industries, and enterprises should make early preparations and make reasonable adjustments to the transportation of goods within the specified time and region. The necessary personnel on duty in the unit and the personnel maintaining the operation of the enterprise should ensure that they arrive at their posts or stay at home before the start of the static management period, and other personnel stay at home and wait for arrangements. The relevant units and industry authorities are responsible for the normal staff, and the list of personnel and vehicles should be reported to the Municipal Prevention and Control Office in advance. After the summary, the Municipal Prevention and Control Office will report to the public security traffic police and issue passes.

　　3. Teachers, students and employees in closed management schools shall be isolated and controlled centrally, and people with disabilities, bedridden and other mobility difficulties shall be arranged to conduct on-site nucleic acid sampling in a unified manner.

　　4. Residents and friends who have symptoms such as fever and cough, please don’t go to the sampling point, report to the local community in time, and on the basis of personal protection, go to the fever clinic of the People’s Hospital for treatment and collect nucleic acid.

　　5. If there are special circumstances such as critically ill patients seeking medical treatment and pregnant women giving birth, please call 120 emergency number in time.

　　6. This full-time nucleic acid test is a preventive test and a concrete measure to implement the requirements of "four mornings". Please actively cooperate with the urban and rural residents, and do not panic, spread rumors, believe in rumors, spread rumors, or stay and watch.

　　7. Please take the initiative to participate in the inspection, otherwise it will affect the decoding and transcoding of personal "red code" and "yellow code" in the later period.

　　8. For residents who do not participate in the full-scale nucleic acid test without justifiable reasons, I will bear corresponding legal responsibilities in accordance with the Law of People’s Republic of China (PRC) on the Prevention and Control of Infectious Diseases and other relevant regulations. Those who refuse to cooperate, do not support the nucleic acid detection work, disturb the order, conceal, lie or falsify information will be strictly investigated for legal responsibility according to law.

　　Safe rest, thank you. Sincerely thank the residents and friends for their understanding, support and cooperation!

　　Jiexiu COVID-19 epidemic prevention and control work leading team office

　　August 26th, 2022 　　

　　Notice of Jiexiu Public Security Bureau on Temporary Road Traffic Control

　　The general public and driver friends:

　　According to the requirements of the epidemic prevention and control leading office of COVID-19 City, Jiexiu City, from 13: 00 on August 26th, 2022 to 24: 00 on August 28th, 2022, the whole city will implement temporary global static management. During the static management period, all motor vehicles will be prohibited from passing on the road (except special vehicles for epidemic prevention and control and performing tasks). At the same time, all intersections in the city will be enabled with red light control and monitoring equipment, and violations of this notice will be dealt with according to law.

　　notice is hereby given (that)

　　Jiexiu bureau of public security

　　August 26th, 2022

comeSource | Yaozhi. com(Reprinted by Cybertron)

Write | 　 three 　

Up to the seventh batch, Hengrui Pharma has won the bid for 20 varieties. During this period, however, the market value continued to be under pressure. Although there are many reasons for losing the bid, it is not that winning the bid can unilaterally bring different profits to the enterprise.

The answer is obvious.

Centralized purchasing is a hurdle that Hengrui can’t cross, and the same is true for the entire pharmaceutical industry. Nowadays, Hengrui innovative drugs are developing rapidly, and a large amount of R&D investment is made every year. Under the guidance of innovative drugs, Hengrui’s short-term pain at present may be just preparing for the bright future.

But is this really the case?

Looking back on the situation in the national medical insurance talks last year, the price of Karelizumab of Hengrui decreased by 85% and that of Esketamine decreased by 68%, but it failed to achieve the expected effect of "exchanging price for quantity". In the end, due to various factors, the sales volume of the product fell short of expectations, and the overall performance declined seriously in 2021. Even in the first quarter of this year, there was no sign of stopping the decline, and 20.93% of the performance decreased year-on-year, which was "Du Jie".

From this point of view, in today’s pharmaceutical market, it is not just generic drugs that are not easy to do, and the situation of innovative drugs is also not optimistic.

Last month, the National Medical Insurance Bureau officially announced the Work Plan for the Adjustment of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List in 2022 and related documents. Hengrui has not recovered from the last shock, but the fifth round of the adjustment of the national medical insurance drug list will begin again.

This time, for Hengrui, is it a turning point, or is it worse?

01

Hengrui 3 new drugs, medical insurance is the only way out?

According to relevant reports, from July 1 last year to June 30 this year, there were about 31 innovative drugs (excluding newly approved indications for listed drugs) approved by domestic enterprises for the first time, including monoclonal antibodies, double antibodies, CAR-T and other drug types, covering many diseases such as cancer and immunity.

Among them, Hengrui has three new drugs that try to advance into the medical insurance catalogue this year, namely, Darceli, Hengglinide and Riverumide.

Heng ge lie Jing

First of all, as two new drugs approved by Hengrui on the same day, both Hengglinide and Darcyril are the first domestic innovative drugs in their respective targets.

The former, Henggliclazide, is also the first SGLT-2 1 new drug independently developed in China, which marks a major breakthrough in the field of treatment in China, and what is more important, of course, is to break the monopoly of foreign companies in the original research of SGLT-2 inhibitors for many years.

According to relevant data, up to now, five SGLT-2 inhibitors have been approved for listing in the domestic hypoglycemic drug market (including compound preparations). Because the approval time of Hengglinide is shorter than that of its predecessors, this has become its most important fatal factor. At present, the market is not fully opened, so it may be even more urgent to superimpose the medical insurance volume in this national medical insurance talk.

In addition, except for the generic drugs of Agglinide tablets in the above table, the other four SGLT-2 inhibitor competing products of Hengrui have been approved to be listed and regarded as over-evaluated, among which both Kagglinide and Engelglinide were included in the fourth batch of centralized purchase. Due to the late listing, the impact of overlapping centralized purchase did not fully appear, and the sales growth rate of the two products in China public medical institutions in 2021 still exceeded 500% and 200%.

Finally, although there are no other SGLT-2 inhibitor Class 1 new drugs approved in China except Hengrui Henggliclazide, the related products of Dongyang Guangyao, Xuanzhu Medicine and other enterprises have also entered Phase III clinical trials, and it is expected that more enterprises will join the competition pattern in the later period. It can be said that this year’s national health insurance talk has become the only hope of Hengrui, a new drug that has not been listed for one year.

Darsili 　　

The situation of another new drug, Dalxil, is also not weaker than that of Hengglinide. According to relevant data, before the approval of Darcyril Tablets, there were four CDK4/6 inhibitors on the global market. Except Trilaciclib, which was approved for bone marrow suppression, the other three inhibitors (Piperacil from Pfizer, Rebocili from Novartis and Agbesi from Lilly) were all used to treat HR+/HER2- breast cancer.

In last year’s national talks on medical insurance, Lilly negotiated successfully before Pfizer, and Abeceli became the first CDK4/6 inhibitor to enter the medical insurance catalogue, which was officially implemented on January 1, 2022. This year, in addition to Abeceli’s soon-approved auxiliary indications, it is highly probable that he will strive to enter the medical insurance list, and the remaining Pipeceli and Rebosi are expected to make many moves in this national talk. At the same time, CDK4/6 is the star target, and the innovative drug market in China has naturally become the priority layout direction of many enterprises. Even some enterprises have prepared generic drugs in order to avoid the overcrowded innovative drug track. On December 18, 2020, Qilu Pharmaceutical’s piperacillin generic drug (the first imitation) was approved by the Food and Drug Administration, waiting for the piperacillin patent to expire in 2023 and enter the market at any time. After Qilu, more than 20 companies also took a fancy to piperacillin generic drugs. Only five companies, including Kelun Pharmaceutical, Osekan, Haosen, Xiansheng and Shanxiang Pharmaceutical, are in the stage of listing application. Even the same innovative drug track also has more than ten products in the clinical stage, such as Zhengda Tianqing, Beierda Pharmaceutical and Jinzhou Aohong. Although the market prospect is attractive, its involution degree is even worse than that of PD-1/L1, and Darceli of Hengrui, even if the national health insurance talk is successful, has little advantage in price and time to market regardless of efficacy. Not surprisingly, the drug of Hengrui will appear at an "amazing" price reduction in this national talk. 　　

Rivirutamide　 　 　　

As for the last Rivirutamide, as a new drug that entered the division time on June 29th, it is mainly used for metastatic hormone-sensitive prostate cancer with high tumor load, and it is also the first new androgen receptor (AR) inhibitor independently developed by China. According to the publicity content of Hengrui, compared with the standard treatment, the overall survival OS of Rivirutamide has been significantly prolonged, and the risk of death and disease progression has been significantly reduced by 42% and 54% respectively. However, it is still unknown whether it can provide a brand-new excellent treatment scheme at present, and it will take some time to be verified by the market.

02

The "involution" of PD-1 situation is still the theme.

Of course, in addition to the above three new drugs, Hengrui’s national talk about PD-1 this year is also one of the most concerned contents and one of the biggest attractions.

First of all, Karelizumab is the only PD-1 monoclonal antibody in the current catalogue that is about to expire. On the premise of the failure of negotiations on nasopharyngeal carcinoma last year, plus the new indications for first-line esophageal cancer and first-line squamous NSCLC this year, the number of items to be discussed increased to four this year.

At the same time, because esophageal cancer and NSCLC are the major diseases with the highest morbidity and mortality in China, it is expected that this year it is very likely to form a "packaged" admission situation-four indications will enter medical insurance at the same time.

Of course, the opposite must be a huge price reduction (refer to the previous PD-1 price reduction and renewal, perhaps even more).

More crucially, since the second half of last year, domestic PD-(L)1 monoclonal antibodies have been approved one after another, and three domestic PD-1 and two domestic PD-L1 may also join the battle in this national medical insurance talk.

This year’s PD-1 national health insurance talk must be another bloody storm.

03

summary

On the whole, perhaps innovation is indeed the way out for Hengrui, but this road is not as smooth as expected.

At least for the time being, Hengrui, who has temporarily passed the centralized mining safely, may face the real problem of "future" in the next step. The innovative drug market, which looks like scenery, is also full of crises, and involution will become the most important rhythm in the next few years or even decades.

In recent years, under the influence of a number of policy adjustments, leading enterprises such as Hengrui are far less able to accurately control and grasp the main trend of the market, and the advantages they can show when competing with biotech enterprises are not as good as before.

The only way to finally change the present situation is time.